FIELD: biotechnology.
SUBSTANCE: disclosed are an anti-SIRPα antibody or an antigen-binding fragment thereof, capable of effectively blocking the binding of SIRPα and CD47, thereby effectively stimulating phagocytosis of tumor cells by macrophages, effectively inhibiting the growth of tumors, and having a good pharmaceutical perspective. Invention also relates to a nucleic acid coding said antibody or fragment thereof, a method of producing the antibody or fragment thereof, a pharmaceutical composition, as well as to the use of the antibody or fragment thereof for treating a tumor.
EFFECT: anti-SIRPα antibody and its use are disclosed.
22 cl, 12 dwg, 8 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-SIRPα ANTIBODIES | 2018 |
|
RU2771174C2 |
| PD-1 BINDING ANTIBODIES AND METHODS OF THEIR USE | 2019 |
|
RU2812280C1 |
| ANTIBODIES BINDING TO PD-1 AND THEIR APPLICATIONS | 2019 |
|
RU2773758C2 |
| BISPECIFIC ANTIBODY | 2020 |
|
RU2814713C2 |
| HUMAN MONOCLONAL ANTIBODIES TO THE PROTEIN OF PROGRAMMED DEATH 1 (PD-1) AND METHODS OF TREATING CANCER USING ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTIC AGENTS | 2016 |
|
RU2732924C2 |
| ANTIBODY FOR SPECIFIC BINDING WITH INTERLEUKIN 4 RECEPTOR | 2017 |
|
RU2774446C2 |
| BISPECIFIC ANTIBODY | 2019 |
|
RU2796019C2 |
| ADVANCED PROCOAGULANT ANTIBODIES | 2019 |
|
RU2810748C2 |
| ANTIBODY AGAINST TNFR2 AND ITS APPLICATION | 2020 |
|
RU2793165C1 |
| MONOCLONAL ANTIBODY TO NAV1.7 | 2019 |
|
RU2776821C2 |
